论文部分内容阅读
目的通过对稳定期阻塞性肺疾病阻塞性肺疾病(COPD)治疗后炎症介质标记物以及COPD分级与气流阻塞程度情况与健康人群对照研究,为临床治疗稳定期COPD提供进一步指导。方法选择2012年1月至2014年1月收治的60例稳定期COPD患者作为观察组,同时募集40例年龄匹配的健康体检者作为对照组。观察组患者进行规律吸入长效支气管舒张剂与吸入肾上腺皮质激素的基础治疗,半年后比较两组患者炎症介质标记物的水平[血清表面活性蛋白D(SPD)、Clara细胞分泌蛋白(CC)-16、血清基质金属蛋白酶(MMP)-9、基质金属蛋白酶组织型抑制剂-1(TIMP-1)]以及COPD分级及气流阻塞程度情况。结果与健康对照组相比,COPD患者血清中SPD显著升高(P<0.05),CC-16水平显著下降(P<0.05),MMP-9水平显著升高(P<0.05),TIMP-1水平显著升高(P<0.01)。观察组、对照组呼吸困难评分分别为(3.4±0.6)分、(3.7±0.7)分,两组比较差异有统计学意义(P<0.05);治疗后,观察组、对照组圣乔治呼吸问卷评分总分分别为(29.7±9.8)分、(54.3±17.9)分,两组比较差异有统计学意义(P<0.01)。结论通过对稳定期COPD治疗后炎症介质标记物以及COPD分级及气流阻塞程度情况与健康人群对照研究,为临床治疗稳定期COPD提供依据,为药物及康复治疗提供参考。
Objective To provide further guidance for the clinical treatment of stable COPD by comparing inflammatory mediators markers of COPD with COPD grading and airflow obstruction and healthy population after stable obstructive pulmonary disease (COPD). Methods Sixty stable COPD patients admitted from January 2012 to January 2014 were selected as the observation group and 40 age-matched healthy subjects were recruited as the control group. The patients in the observation group were treated with the regular inhalation of long-acting bronchodilator and inhaled corticosteroid. After six months, the levels of inflammatory mediators (SPD, Clara cell secretory protein (CC) 16, serum matrix metalloproteinase (MMP) -9, tissue inhibitor of tissue inhibitor of metalloproteinase-1 (TIMP-1)], and COPD grading and airflow obstruction. Results Compared with healthy control group, serum SPD in COPD patients was significantly increased (P <0.05), CC-16 levels were significantly decreased (P <0.05), MMP-9 was significantly increased The level was significantly higher (P <0.01). The scores of dyspnea in observation group and control group were (3.4 ± 0.6) points and (3.7 ± 0.7) points respectively, there was significant difference between the two groups (P <0.05). After treatment, the observation group and control group St. George’s Respiratory Questionnaire The score was (29.7 ± 9.8) points and (54.3 ± 17.9) points, respectively. The difference between the two groups was statistically significant (P <0.01). Conclusion This study provides a basis for the clinical treatment of stable COPD by comparing inflammatory markers and the classification of COPD and the degree of obstruction of airflow obstruction with healthy people after stable COPD treatment, providing a reference for drugs and rehabilitation.